Online citations, reference lists, and bibliographies.
← Back to Search

Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: Formulation, Characterization, And Release Characteristics

V. Hoffart, N. Ubrich, C. Simonin, V. Babak, C. Vigneron, M. Hoffman, T. Lecompte, P. Maincent
Published 2002 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT The aim of the present work was to investigate the preparation of low molecular weight heparin (LMWH) nanoparticles (NP) as potential oral heparin carriers. The NP were formulated using an ultrasound probe by water-in-oil-in-water (w/o/w) emulsification and solvent evaporation with two biodegradable polymers [poly-ε-caprolactone, PCL and poly(d,l-lactic-co-glycolic acid) 50/50, PLGA] and two non-biodegradable positively charged polymers (Eudragit RS and RL) used alone or in combination. The mean diameter of LMWH-loaded NP ranged from 240 to 490 nm and was dependent on the reduced viscosity of the polymeric organic solution. The surface potential of LMWH NP prepared with Eudragit polymers used alone or blended with PCL and PLGA was changed dramatically from strong positive values obtained with unloaded NP to negative values. The highest encapsulation efficiencies were observed when Eudragit polymers took part in the composition of the polymeric matrix, compared with PCL and PLGA NP exhibiting low LMWH entrapment. The in vitro LMWH release in phosphate buffer from all formulations ranged from 10 to 25% and was more important (two- to threefold) when esterase was added into the dissolution medium. The in vitro biological activity of released LMWH, determined by the anti-factor Xa activity with a chromogenic substrate, was preserved after the encapsulation process, making these NP good candidates for oral administration.
This paper references
10.1182/blood.v59.6.1239.1239
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.
C. J. Carter (1982)
10.1016/0378-5173(81)90036-3
An evaluation of the oral administration of commercial and fractionated heparin samples in rats
A. Morton (1981)
10.1378/CHEST.114.5_SUPPLEMENT.489S
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
J. Hirsh (1998)
10.1161/HC0202.101988
In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits
Y. Jiao (2002)
Dosage de l’Héparine: Étude Critique
M. Ardry (1967)
10.1055/S-0038-1647302
Heparin effect on bone density.
Jeffrey S. Ginsberg (1990)
10.1161/01.CIR.101.22.2658
Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis.
M. D. Gonze (2000)
10.3109/02652049009021845
Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment.
R. Alex (1990)
10.1080/107175401316906892
Preparation and In Vitro Evaluation of Heparin-Loaded Polymeric Nanoparticles
Y. Jiao (2001)
Delivery System for Pharmacological Agents Encapsulated with Proteinoids
S. Steiner (1990)
10.1016/0031-6989(85)90086-4
Olive oil-provoked bile-dependent absorption of heparin from gastro-intestinal tract in rats.
S. Guarini (1985)
10.1081/DDC-120014740
Preparation and Characterization of Heparin-Loaded Polymeric Microparticles
Y. Jiao (2002)
10.1007/BF00280041
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
G. Handeland (2004)
Dosage de l'He´parine: É tude Critique
M Ardry (1967)
Encapsulation of WaterSoluble Drugs by a Modified Solvent Evaporation Method. I
R. Alex (1989)
10.1016/0049-3848(77)90150-5
Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.
A. Teien (1977)
Mechanisms of Action, Pharmacokinetics, Dosing Considerations, Monitoring
J Hirsh (1998)
Mechanisms of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy and Safety
J. Hirsh (1998)
10.1016/S0168-3659(99)00012-7
Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release.
M. Polakovič (1999)
10.1172/JCI115198
Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
M. Sobel (1991)
10.1016/S0168-3659(97)00101-6
Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP
A. Leone-Bay (1998)
10.1016/S0967-2109(00)00144-7
Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.
S. Money (2001)
10.1016/0049-3848(89)90014-5
New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds.
A. Dal Pozzo (1989)
10.1161/01.CIR.98.16.1610
Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans.
R. Baughman (1998)
10.1016/0167-4889(85)90177-6
Binding and endocytosis of heparin by human endothelial cells in culture.
T. Bârzu (1985)
10.3181/00379727-111-27900
Enhancement of Jejunal Absorption of Heparinoid by Sodium Ethylenediaminetetraacetate in the Dog.∗
C. Tidball (1962)
10.1248/CPB.30.2245
Oral administration of liposomally-entrapped heparin to beagle dogs.
M. Ueno (1982)



This paper is referenced by
Formulation and evaluation of nanoparticles of some anticancer drugs for targeted delivery
Riddhi M. Dave (2013)
ETOPOSIDE-LOADED NANOPARTICLES MADE FROM POLY-E- CAPROLACTONE (PCL): FORMULATION, CHARACTERIZATION, IN VITRO DRUG RELEASE FOR CONTROLLED DRUG DELIVERY SYSTEM
T. Mallamma (2014)
To Study Effect of Process Variables on Preparation of Desmopressin Loaded Nanoparticles Using Box-Behnken Design
D. Desai (2016)
10.3109/02652040902751125
Preparation and in vitro–in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles
Eliza Główka (2010)
10.1016/J.MENCOM.2008.01.015
Zeta-potential and morphology of electrospun nano- and microfibers from biopolymers and their blends used as scaffolds in tissue engineering
C. Vaquette (2008)
10.5012/BKCS.2011.32.5.1465
The Evaluation of Fabrication Parameters Process Effect on the Formation of Poly(lactic-co-glycolic acid) (PLGA) Microspheres
Trinh-Quang Bao (2011)
10.5681/apb.2012.007
Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability.
B. D. Loveymi (2012)
10.1081/DDC-200047802
Formulation of Insulin-Loaded Polymeric Nanoparticles Using Response Surface Methodology
D. Attivi (2005)
10.1016/J.MENCOM.2008.07.007
Polycondensation in tetradecaethoxyhexasiloxane adsorption layers at the methylene chloride/water interface under alkaline conditions: application to the formulation of hollow microcapsules
V. Babak (2008)
10.1080/02652040802465719
Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system
S. S. Lanke (2009)
10.1016/j.jddst.2020.102145
Surface Modification of PLGA Nanoparticles with Chitosan or Eudragit® RS 100: Characterization, prolonged release, cytotoxicity, and enhanced antimicrobial activity
Gülsel Yurtdaş-Kırımlıoğlu (2020)
10.1007/s40005-014-0129-0
The effect of Eudragit type on BSA-loaded PLGA nanoparticles
Min-Ho Park (2014)
10.4103/2230-973X.187351
Preparation and evaluation of a novel oral delivery system for low molecular weight heparin
N. Lavanya (2016)
POLYMERIC NANOPARTICLES AS POTENTIAL CARRIERS FOR TOPICAL DELIVERY OF COLCHICINE: DEVELOPMENT AND IN VITRO CHARACTERIZATION
R. Khalil (2014)
10.1016/j.ejpb.2009.07.009
Composite microparticles with in vivo reduction of the burst release effect.
A. Sheikh Hassan (2009)
he characteristics and improved intestinal permeability of vancomycin LGA-nanoparticles as colloidal drug delivery system
arvin Zakeri-Milania (2012)
RESULTS & DISCUSSION OF ETOPOSIDE NANOFORMULATIONS
(2015)
10.1166/JBN.2014.1806
Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles.
M. Durán‐Lobato (2014)
10.1155/2014/683153
Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies
Vijay D. Wagh (2014)
10.3109/10837450.2015.1041044
Formulation and in vitro characterization of poly(dl-lactide-co-glycolide)/Eudragit RLPO or RS30D nanoparticles as an oral carrier of levofloxacin hemihydrate
Azza A. Hasan (2016)
Application of nanotechnology in device promotion in cardiology: A promising horizon for nanocardiology toward personalized medicine
P. Keyhanvar (2015)
10.1016/J.JCONREL.2006.03.020
Oral bioavailability of a low molecular weight heparin using a polymeric delivery system.
V. Hoffart (2006)
10.1016/j.colsurfb.2012.06.038
Poly(ε-caprolactone), Eudragit® RS 100 and poly(ε-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz.
Katia P. Seremeta (2013)
10.1016/J.JDDST.2015.06.020
Reduction of the in vivo burst release of insulin-loaded microparticles
A. S. Hasan (2015)
10.1016/j.pneurobio.2008.12.002
Delivery of peptide and protein drugs over the blood–brain barrier
I. Brasnjevic (2009)
10.4172/2157-7048.1000228
Nanoencapsulation of Insulin Using Blends of Biodegradable Polymers andIn Vitro Controlled Release of Insulin
V. Rahmani (2015)
10.3109/1061186X.2012.763040
In vitro and in vivo investigation of low molecular weight heparin–alginate beads for oral administration
Canan Iskenderoğlu (2013)
10.1602/neurorx.2.1.108
Drug transport to brain with targeted nanoparticles
J. Olivier (2011)
10.3109/03639045.2012.681383
Influence of polymer blends on the characterization of gliclazide – encapsulated into poly (Æ-caprolactone) microparticles
N. Barakat (2013)
10.1080/03639040601031882
Preparation, Characterization, and Scale-up of Ketoconazole with Enhanced Dissolution and Bioavailability
E. J. Elder (2007)
10.1016/j.jconrel.2011.01.010
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
P. Aksungur (2011)
PREPARATION OF DICLOFENAC SODIUM COMPOSITE MICROPARTICLES WITH IMPROVED INITIAL RELEASE PROPERTY
M. Jelvehgari (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar